What is Intercept Pharmaceuticals?
Intercept Pharmaceuticals operates as a biopharmaceutical company specializing in the development and commercialization of therapeutics targeting liver diseases. The company focuses on addressing significant unmet medical needs within hepatology through targeted drug development and clinical research initiatives. By concentrating its efforts on liver-related conditions, Intercept has built a specialized expertise in understanding disease mechanisms and developing treatment approaches that address complex pathophysiology in this therapeutic area. The company's research and development efforts center on identifying novel mechanisms of action and advancing compounds through clinical development stages. Intercept's approach combines rigorous scientific investigation with a commitment to understanding the underlying biology of liver diseases, enabling the organization to pursue therapeutic candidates with meaningful clinical potential. This focused strategy has allowed the company to develop a pipeline of investigational medicines designed to address various hepatic conditions affecting patient populations globally. Intercept's commercial operations extend to bringing approved therapeutics to healthcare providers and patients, with the company maintaining capabilities in manufacturing, regulatory affairs, and market access.
How much funding has Intercept Pharmaceuticals raised?
Intercept Pharmaceuticals has raised a total of $1.5B across 11 funding rounds:
Series B
$25M
Series C
$30M
Stock Offering
$75M
Stock Offering
$61.7M
Stock Offering
$183.3M
Debt
$447.7M
Stock Offering
$250M
Stock Offering
$200M
Debt
$210.4M
Series B (2010): $25M supported by Genextra S.p.A
Series C (2012): $30M featuring Genextra S.p.A and OrbiMed
Stock Issuance/Offering (2012): $75M, investors not publicly disclosed
Stock Issuance/Offering (2013): $61.7M, investors not publicly disclosed
Stock Issuance/Offering (2014): $183.3M, investors not publicly disclosed
Debt (2016): $447.7M, investors not publicly disclosed
Stock Issuance/Offering (2018): $250M featuring Samsara BioCapital, L.P. and Genextra S.p.A
Stock Issuance/Offering (2019): $200M, investors not publicly disclosed
Debt (2019): $210.4M, investors not publicly disclosed
Key Investors in Intercept Pharmaceuticals
Genextra S.p.A
Genextra is a privately owned holding company that invests in early-stage life science companies. The company focuses on identifying innovative research in life sciences and aims to advance novel therapies and technologies through successful business initiatives. Their mission is to foster the development of new therapies and tools by creating companies that support this innovation. Genextra targets clients in the life science sector, particularly those involved in research and development.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services, bringing together investment professionals with extensive experience in life sciences and healthcare business development. The firm's investment approach reflects a comprehensive understanding of healthcare innovation cycles and market dynamics.
Balyasny Asset Management
Balyasny Asset Management is a global investment firm focused on delivering consistent returns for institutional investors. The company uses deep research, advanced technology, and disciplined risk management to identify opportunities across financial markets, including equities, macro strategies, and quantitative trading while fostering a collaborative and performance driven culture.
What's next for Intercept Pharmaceuticals?
The substantial enterprise-level financing and recent strategic investment indicate Intercept Pharmaceuticals is likely in a growth or scaling phase, potentially preparing for late-stage clinical trials, commercial launch of new therapies, or further pipeline expansion. The company's deep specialization in liver diseases positions it to capitalize on significant unmet medical needs within this therapeutic area. Future strategic moves may involve further research and development, potential partnerships or acquisitions to bolster its pipeline, and continued efforts to bring its therapeutic candidates to market. The consistent flow of capital suggests a strong belief in the company's scientific foundation and its potential to deliver impactful treatments for patients suffering from liver conditions.
See full Intercept Pharmaceuticals company page
